Literature DB >> 27524465

The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma.

Tatsuya Minami1, Ryosuke Tateishi2, Ryo Nakagomi1, Naoto Fujiwara1, Masaya Sato1, Kenichiro Enooku1, Hayato Nakagawa1, Yoshinari Asaoka1, Yuji Kondo1, Shuichiro Shiina3, Kazuhiko Koike1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27524465     DOI： 10.1016/j.jhep.2016.07.043

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  29 in total

1.  Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.

Authors:  N Saraiya; A C Yopp; N E Rich; M Odewole; N D Parikh; A G Singal
Journal:  Aliment Pharmacol Ther       Date:  2018-05-30       Impact factor: 8.171

Review 2.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

3.  Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma.

Authors:  Xavier Adhoute; Paul Castellani; Marc Bourlière
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-18

4.  Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.

Authors:  Winnie Y Zou; Kati Choi; Jennifer R Kramer; Xian Yu; Yumei Cao; Hashem B El-Serag; Fasiha Kanwal
Journal:  Dig Dis Sci       Date:  2019-04-30       Impact factor: 3.199

5.  Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk.

Authors:  Marcus-Alexander Wörns; Peter Robert Galle; Stefan Zeuzem; Peter Schirmacher; Michael Manns; Arndt Vogel
Journal:  Dtsch Arztebl Int       Date:  2017-09-04       Impact factor: 5.594

Review 6.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

Review 7.  AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.

Authors:  Amit G Singal; Joseph K Lim; Fasiha Kanwal
Journal:  Gastroenterology       Date:  2019-03-13       Impact factor: 22.682

8.  Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy.

Authors:  Carmen M Preda; Cristian Baicus; Irina Sandra; Alexandru Oproiu; Teodora Manuc; Ileana Constantinescu; Daniel Gavrila; Mircea Diculescu; Radu Dumitru; Catalin Vasilescu; Cristian Tieranu; Doina Istratescu; Theodor Voiosu; Mircea Manuc
Journal:  United European Gastroenterol J       Date:  2019-03-29       Impact factor: 4.623

9.  Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.

Authors:  Kenji Ikeda; Yusuke Kawamura; Masahiro Kobayashi; Yoko Kominami; Shunichiro Fujiyama; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Satoshi Saitoh; Fumitaka Suzuki; Yoshiyuki Suzuki; Yasuji Arase; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2017-09-07       Impact factor: 3.199

10.  Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.

Authors:  Yoshihiko Ooka; Kanda Miho; Obi Shuntaro; Masato Nakamura; Sadahisa Ogasawara; Eiichiro Suzuki; Shin Yasui; Tetsuhiro Chiba; Makoto Arai; Tatsuo Kanda; Hitoshi Maruyama; Osamu Yokosuka; Naoya Kato; Hitoshi Mochizuki; Masao Omata
Journal:  Hepatol Int       Date:  2018-09-21       Impact factor: 6.047
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.